Mapping health assessment questionnaire disability index onto EQ-5D-5L in China
暂无分享,去创建一个
[1] N. Luo,et al. Mapping the obesity problems scale to the SF-6D: results based on the Scandinavian Obesity Surgery Registry (SOReg) , 2022, The European Journal of Health Economics.
[2] P. McNamee,et al. Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data , 2022, The European Journal of Health Economics.
[3] Shuyang Zhang,et al. Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia , 2021, Quality of Life Research.
[4] X. Zeng,et al. [The challenges and opportunities for the management of rheumatoid arthritis in China: an annual report of 2019]. , 2021, Zhonghua nei ke za zhi.
[5] Shuyang Zhang,et al. Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly , 2021, The European Journal of Health Economics.
[6] S. Ye,et al. Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World , 2020, Journal of inflammation research.
[7] E. Wong,et al. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas , 2020, The European Journal of Health Economics.
[8] Jingyang Li,et al. Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China , 2020, Annals of translational medicine.
[9] Chuan Yu,et al. [Evaluation of Reliability and Validity of EQ-5D-5L Based on Residents in Southwest China]. , 2020, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.
[10] N. Kragh,et al. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study , 2020, Quality of Life Research.
[11] S. Ghabri,et al. Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs , 2020, PharmacoEconomics.
[12] P. Dixon,et al. Mapping to Quality of Life and Capability Measures in Cataract Surgery Patients: From Cat-PROM5 to EQ-5D-3L, EQ-5D-5L, and ICECAP-O Using Mixture Modelling , 2020, MDM policy & practice.
[13] Zhichao Shi,et al. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients , 2020, Medicine.
[14] P. Cheung,et al. Sociodemographic factors as determinants of disease, disability and quality of life trajectories in early rheumatoid arthritis: A multi‐ethnic inception cohort study , 2019, International journal of rheumatic diseases.
[15] Jingyang Li,et al. A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients , 2019, Medicine.
[16] J. Piercy,et al. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis , 2019, The European Journal of Health Economics.
[17] A. Wailoo,et al. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] Luan Luan,et al. Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population , 2018, Quality of Life Research.
[19] K. Pavelka,et al. Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis , 2018, The Patient - Patient-Centered Outcomes Research.
[20] A. Wailoo,et al. Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] E. Galíndez,et al. THU0109 Updated estimation of the EQ5D quality of life questionnaire utility values through HAQ-DI mapping for spain , 2017 .
[22] A. Hawton,et al. Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values , 2017, PharmacoEconomics - Open.
[23] Wendong Chen,et al. Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. , 2017, Journal of comparative effectiveness research.
[24] Nan Luo,et al. Estimating an EQ-5D-5L Value Set for China. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] Liren Li,et al. The correlations of socioeconomic status, disease activity, quality of life, and depression/anxiety in Chinese patients with rheumatoid arthritis , 2017, Psychology, health & medicine.
[26] I. McInnes,et al. Rheumatoid arthritis , 2016, The Lancet.
[27] S. Bang,et al. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data , 2016, Rheumatology International.
[28] J. Richardson,et al. Mapping between 6 Multiattribute Utility Instruments , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.
[29] N. Luo,et al. Valuing Health-Related Quality of Life in Type 2 Diabetes Patients in China , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.
[30] Michael Herdman,et al. Interpretation and use of the 5-level EQ-5D response labels varied with survey language among Asians in Singapore. , 2015, Journal of clinical epidemiology.
[31] Mark Oppe,et al. The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration , 2015, PharmacoEconomics.
[32] Andrea Manca,et al. Prediction of patient‐reported outcome measures via multivariate ordered probit models , 2015 .
[33] J. Brazier,et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.
[34] J. Thompson,et al. Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[35] Allan Wailoo,et al. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis , 2013, Rheumatology.
[36] J. Zajicek,et al. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[37] Matthias Hunger,et al. Longitudinal beta regression models for analyzing health-related quality of life scores over time , 2012, BMC Medical Research Methodology.
[38] Roberta Ara,et al. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[40] Andrea Manca,et al. Regression Estimators for Generic Health-Related Quality of Life and Quality-Adjusted Life Years , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[41] Donna Rowen,et al. Mapping onto Eq-5 D for patients in poor health , 2010, Health and quality of life outcomes.
[42] A. Silman,et al. UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .
[43] Aki Tsuchiya,et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.
[44] T. Tasiemski,et al. Assessment of objective and subjective quality of life in people with rheumatoid arthritis - preliminary study. , 2009, Ortopedia, traumatologia, rehabilitacja.
[45] C. Croux,et al. Robust Regression in Stata , 2008 .
[46] Vahram Ghushchyan,et al. Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative Sample , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[47] A. Boyles,et al. National Institute of Environmental Health Sciences , 2008 .
[48] J. Pater. Quality of life and pharmacoeconomics in clinical trials , 1996 .
[49] V. Yohai. HIGH BREAKDOWN-POINT AND HIGH EFFICIENCY ROBUST ESTIMATES FOR REGRESSION , 1987 .
[50] D. H. Lee,et al. The National Institute of Environmental Health Sciences. , 1970, American Industrial Hygiene Association journal.
[51] G. K. Hirst. British Medical Journal , 1927 .
[52] H. Hasegawa. Assessment of Disease Activity, Structural Damage, and Function in Rheumatoid Arthritis. , 2018, Methods in molecular biology.
[53] [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. , 2018, Zhonghua nei ke za zhi.
[54] Andrea Manca,et al. Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[55] Xie Xiao-ping. Disease Burden and Quality of Life of Rheumatoid Arthritis in China: A Systematic Review , 2013 .
[56] X. Badia,et al. Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[57] Patrick W. Sullivan,et al. US General Population Preferences in a Nationally Representative Sample , 2009 .
[58] P. Fayers,et al. Quality of Life: The assessment, analysis and interpretation of patient-reported outcomes , 2007 .
[59] J. Fries,et al. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. , 2003, The Journal of rheumatology.
[60] M. Prevoo,et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[61] C. L. Callahan,et al. The quality of life. , 1970, Nursing outlook.
[62] Douglas G. Altman,et al. Explanation and Elaboration , 2022 .